These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 14705183)
1. Stability of PEGylated salmon calcitonin in nasal mucosa. Na DH; Youn YS; Park EJ; Lee JM; Cho OR; Lee KR; Lee SD; Yoo SD; DeLuca PP; Lee KC J Pharm Sci; 2004 Feb; 93(2):256-61. PubMed ID: 14705183 [TBL] [Abstract][Full Text] [Related]
2. Proteolysis of human calcitonin in excised bovine nasal mucosa: elucidation of the metabolic pathway by liquid secondary ionization mass spectrometry (LSIMS) and matrix assisted laser desorption ionization mass spectrometry (MALDI). Lang SR; Staudenmann W; James P; Manz HJ; Kessler R; Galli B; Moser HP; Rummelt A; Merkle HP Pharm Res; 1996 Nov; 13(11):1679-85. PubMed ID: 8956334 [TBL] [Abstract][Full Text] [Related]
3. Nasal absorption and pharmacokinetic disposition of salmon calcitonin modified with low molecular weight polyethylene glycol. Shin BS; Jung JH; Lee KC; Yoo SD Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):957-60. PubMed ID: 15304989 [TBL] [Abstract][Full Text] [Related]
4. Degradation of salmon calcitonin in rat kidney and liver homogenates. Liao S; Zhang ZQ; Ruan JX; Qi JK; Liu KL Pharmazie; 2008 Oct; 63(10):743-7. PubMed ID: 18972837 [TBL] [Abstract][Full Text] [Related]
5. High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation. Youn YS; Na DH; Lee KC J Control Release; 2007 Feb; 117(3):371-9. PubMed ID: 17207880 [TBL] [Abstract][Full Text] [Related]
6. Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins. Lee KC; Moon SC; Park MO; Lee JT; Na DH; Yoo SD; Lee HS; DeLuca PP Pharm Res; 1999 Jun; 16(6):813-8. PubMed ID: 10397599 [TBL] [Abstract][Full Text] [Related]
7. Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats. Lee KC; Park MO; Na DH; Youn YS; Lee SD; Yoo SD; Lee HS; DeLuca PP Calcif Tissue Int; 2003 Dec; 73(6):545-9. PubMed ID: 14508623 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization and biodistribution studies of (125)I-radioiodinated di-PEGylated bone targeting salmon calcitonin analogue in healthy rats. Yang Y; Bhandari KH; Panahifar A; Doschak MR Pharm Res; 2014 May; 31(5):1146-57. PubMed ID: 24357414 [TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization and in vivo activity of salmon calcitonin coconjugated with lipid and polyethylene glycol. Cheng W; Lim LY J Pharm Sci; 2009 Apr; 98(4):1438-51. PubMed ID: 18704953 [TBL] [Abstract][Full Text] [Related]
10. Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats. Bhandari KH; Newa M; Chapman J; Doschak MR J Control Release; 2012 Feb; 158(1):44-52. PubMed ID: 22001608 [TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. Lee KC; Tak KK; Park MO; Lee JT; Woo BH; Yoo SD; Lee HS; DeLuca PP Pharm Dev Technol; 1999 May; 4(2):269-75. PubMed ID: 10231888 [TBL] [Abstract][Full Text] [Related]
12. Identification of the modifying sites of mono-PEGylated salmon calcitonins by capillary electrophoresis and MALDI-TOF mass spectrometry. Na DH; Park MO; Choi SY; Kim YS; Lee SS; Yoo SD; Lee HS; Lee KC J Chromatogr B Biomed Sci Appl; 2001 Apr; 754(1):259-63. PubMed ID: 11318423 [TBL] [Abstract][Full Text] [Related]
13. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. Youn YS; Kwon MJ; Na DH; Chae SY; Lee S; Lee KC J Control Release; 2008 Jan; 125(1):68-75. PubMed ID: 18023905 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, characterization and in-vivo activity of a novel salmon calcitonin conjugate containing a novel PEG-lipid moiety. Cheng W; Lim LY J Pharm Pharmacol; 2010 Mar; 62(3):296-304. PubMed ID: 20487211 [TBL] [Abstract][Full Text] [Related]
15. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. Youn YS; Jung JY; Oh SH; Yoo SD; Lee KC J Control Release; 2006 Sep; 114(3):334-42. PubMed ID: 16884808 [TBL] [Abstract][Full Text] [Related]
16. PK/PD modelling of comb-shaped PEGylated salmon calcitonin conjugates of differing molecular weights. Ryan SM; Frías JM; Wang X; Sayers CT; Haddleton DM; Brayden DJ J Control Release; 2011 Jan; 149(2):126-32. PubMed ID: 20946924 [TBL] [Abstract][Full Text] [Related]
17. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl-beta-cyclodextrins. Sinswat P; Tengamnuay P Int J Pharm; 2003 May; 257(1-2):15-22. PubMed ID: 12711157 [TBL] [Abstract][Full Text] [Related]
18. Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly(ethylene glycol) methyl ether methacrylate) yields a bioactive stable conjugate. Ryan SM; Wang X; Mantovani G; Sayers CT; Haddleton DM; Brayden DJ J Control Release; 2009 Apr; 135(1):51-9. PubMed ID: 19168100 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of HPβCD-PEG microparticles for salmon calcitonin administration via pulmonary delivery. Tewes F; Gobbo OL; Amaro MI; Tajber L; Corrigan OI; Ehrhardt C; Healy AM Mol Pharm; 2011 Oct; 8(5):1887-98. PubMed ID: 21882837 [TBL] [Abstract][Full Text] [Related]
20. Design of salmon calcitonin particles for nasal delivery using spray-drying and novel supercritical fluid-assisted spray-drying processes. Cho W; Kim MS; Jung MS; Park J; Cha KH; Kim JS; Park HJ; Alhalaweh A; Velaga SP; Hwang SJ Int J Pharm; 2015 Jan; 478(1):288-296. PubMed ID: 25445994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]